Loading…
← CockpitCompetitor Analysis › NAN.AX Nanosonics LimitedOpen in the cockpit ↗

Nanosonics LimitedNAN.AXCompetitor analysis, valuation and peers

Australia · AUD·Health Care›Medical Specialties
Momentum weak 36
Mkt cap
$599M
US dollars, full cap
Free float
72%
of shares outstanding
$/day
$1.71M
20-day average traded
Fwd P/E
98.6×
forward earnings
ROIC−WACC
+1.5 pp
WACC 10.8%
Hurdle
+29 pp
Req g minus delivered
Next earnings
97 days
23 Feb 2027
Close · AUDA$2.96
1D+1.4%
1W+6.5%
1M-1.3%
3M-18.5%
6M-4.2%
YTD-25.4%
1Y-24.7%
ATR %3.4%
52w lowhigh32.7% off high

What Nanosonics does

Employees: 508

Nanosonics at a glance

Size Nanosonics (NAN.AX) is an Australia Health Care company (Medical Specialties) with a market value of $599M, the 232nd largest of 317 Australia companies the cockpit tracks. Shares closed at A$2.96 on 18 Nov 2026.

Performance Over six months the shares fell 4.2%, against -20.3% for the median peer and +1.2% for the Australia market (cap-weighted) — 9th highest of 19 in its peer set.

Growth Revenue grew 2.6% over the last twelve months (peer median +16.1%); the operating margin is 7.4% (peer median 8.5%).

Valuation It trades at 98.6× forward earnings against a peer median of 20.0× (most expensive of 13).

Price implies For today's price to make sense, revenue must grow about 35% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +29 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.5 points above its cost of capital (10.8% WACC).

Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026NAN.AX 95Peer median 81
Six months, rebased to 100: Nanosonics against the median of its 20 peers (local-currency closes).

Nanosonics financials

Reported figures in AUD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
RevenueA$203MA$203MA$198MA$172MA$168M
Revenue growth—+3%+16%+2%—
Gross profitA$156MA$149MA$148MA$127MA$126M
EBITDAA$23.7MA$23.7MA$24.5MA$16.0MA$25.1M
Net incomeA$17.8MA$17.8MA$20.7MA$13.0MA$19.9M
Free cash flowA$17.4MA$17.4MA$35.3MA$20.3MA$19.7M
Capital expenditureA$5.14MA$5.14MA$8.72MA$2.52MA$3.57M
Total debtn/aA$23.1MA$7.69MA$9.30MA$10.7M

Quarterly statements and history in the cockpit →

Nanosonics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%MEDISGHTTCMD688581300314OBIOXVIVO688236300952PACB47283012356031221789300869QDELSNTNAN.AX6-month return →1-month return →
Up and to the right = strong over both horizons. Nanosonics is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%50×100×MEDITCMD688581300314XVIVO6882363009523012351789QDEL605369SNTNAN.AXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Nanosonics is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%MEDITCMD688581XVIVO68823647281789300869605369SNTNAN.AXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Nanosonics is the large dot.

Nanosonics competitors and peer comparison

How Nanosonics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Nanosonics against its 20 peers (data as of 18 Nov 2026)
MeasureNAN.AXPeer medianRank in peer set
1-month return-1.3%-5.5%8th highest of 19
6-month return-4.2%-20.3%9th highest of 19
Distance from 52-week high-32.7%-34.3%10th highest of 20
Revenue growth (TTM)+2.6%+16.1%6th lowest of 20
Operating margin7.4%8.5%9th lowest of 20
Forward P/E98.6×20.0×most expensive of 13
Growth the price implies (Req g, 7 yrs)35.3%0.3%2nd most demanding of 11
Growth delivered (Del g)+6.7%+13.2%5th lowest of 11
Hurdle (Req g minus delivered)+28.6 pp-13.2 pp2nd most demanding of 11
ROIC minus cost of capital+1.5 pp+0.3 pp10th highest of 19
EV / EBITDA32.2×13.2×most expensive of 8
Net debt / EBITDA-5.6×-0.7×least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Nanosonics NAN.AXAustralia$599M-4%+3%7%98.6×35.3%+6.7%
Medistim MEDI.OLNorway$599M+32%+19%29%31.8×-1.2%+14.5%
Sight Sciences SGHTUnited States$599M+122%+16%-30%n/an/an/a
Sahajanand Medical Technologies SMT.NSIndia$595Mn/an/an/an/an/an/a
vVARDIS VVVVUnited States$594Mn/a+148%-72%n/an/an/a
Tactile Systems Technology TCMDUnited States$592M+6%+14%9%21.1×8.4%+12.0%
Hangzhou AGS MedTech 688581.SSChina$590M-22%-18%33%18.9×0.4%+27.8%
Ningbo David Medical Device 300314.SZChina$589M+25%+19%11%12.0×n/an/a
Orchestra BioMed OBIOUnited States$587M+87%+1,007%-195%n/an/an/a
Xvivo Perfusion XVIVO.STSweden$611M-32%+18%12%53.1×35.9%+35.2%
Beijing Chunlizhengda Medical Instruments 688236.SSChina$618M-27%-13%31%17.4×-8.5%+2.2%
Jiangsu Hanvo Safety Product 300952.SZChina$575M-38%+6%8%39.7×n/an/a
Pacific Biosciences of California PACBUnited States$573M+54%+4%-98%n/an/an/a
SunMax Biotechnology 4728.TWOTaiwan$630M0%+19%51%n/a-2.6%+18.8%
Wuhan Huakang Century Clean Technology 301235.SZChina$563M-57%+28%7%33.7×n/an/a
Cowealth Medical China 603122.SSChina$562M-34%-18%-5%n/an/an/a
AK Medical 1789.HKHong Kong$642M-23%+16%26%10.5×-11.5%+6.7%
Contec Medical Systems 300869.SZChina$547M-26%-2%-16%n/a15.0%-19.8%
QuidelOrtho QDELUnited States$657M-20%-5%-2%10.7×n/an/a
Zhejiang Gongdong Medical Technology 605369.SSChina$542M-21%+6%9%23.5×10.2%+6.5%
Synektik SNT.WAPoland$662M+10%+32%24%13.8×0.2%+47.5%

Questions

Which companies are Nanosonics's closest peers?
The cockpit's peer set: Medistim (MEDI.OL), Sight Sciences (SGHT), Sahajanand Medical Technologies (SMT.NS), vVARDIS (VVVV), Tactile Systems Technology (TCMD), Hangzhou AGS MedTech (688581.SS), Ningbo David Medical Device (300314.SZ), Orchestra BioMed (OBIO).
Is Nanosonics expensive compared with its peers?
On forward p/e it trades at 98.6× against a peer median of 20.0×, most expensive of 13 in its peer set. For today's price to make sense, revenue must grow about 35% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +29 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Nanosonics stock performed?
Over six months to 18 Nov 2026 the shares returned -4.2% against -20.3% for the median peer; over one year -24.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.